JP2021527090A - 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物 - Google Patents

老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物 Download PDF

Info

Publication number
JP2021527090A
JP2021527090A JP2020569002A JP2020569002A JP2021527090A JP 2021527090 A JP2021527090 A JP 2021527090A JP 2020569002 A JP2020569002 A JP 2020569002A JP 2020569002 A JP2020569002 A JP 2020569002A JP 2021527090 A JP2021527090 A JP 2021527090A
Authority
JP
Japan
Prior art keywords
aminosterol
dose
subject
derivative
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020569002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527090A5 (https=
Inventor
マイケル ザスロフ、
デニス バーブット、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enterin Inc
Original Assignee
Enterin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterin Inc filed Critical Enterin Inc
Publication of JP2021527090A publication Critical patent/JP2021527090A/ja
Publication of JP2021527090A5 publication Critical patent/JP2021527090A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2020569002A 2018-06-13 2019-06-13 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物 Pending JP2021527090A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862684496P 2018-06-13 2018-06-13
US62/684,496 2018-06-13
PCT/US2019/036946 WO2019241503A1 (en) 2018-06-13 2019-06-13 Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration

Publications (2)

Publication Number Publication Date
JP2021527090A true JP2021527090A (ja) 2021-10-11
JP2021527090A5 JP2021527090A5 (https=) 2022-04-22

Family

ID=68838925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020569002A Pending JP2021527090A (ja) 2018-06-13 2019-06-13 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物

Country Status (11)

Country Link
US (2) US20190381071A1 (https=)
EP (1) EP3806862A4 (https=)
JP (1) JP2021527090A (https=)
KR (1) KR20210009422A (https=)
CN (1) CN112566641A (https=)
AU (1) AU2019285065A1 (https=)
BR (1) BR112020025296A2 (https=)
CA (1) CA3103463A1 (https=)
MX (1) MX2020013614A (https=)
SG (1) SG11202012343TA (https=)
WO (1) WO2019241503A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
WO2020028810A1 (en) * 2018-08-03 2020-02-06 Enterin Laboratories Compositions and methods for treating brain-gut disorders
US20210260078A1 (en) * 2018-08-03 2021-08-26 Philadelphia Low dosage intranasal aminosterol dosage forms and methods of using the same
CN110827282B (zh) * 2020-01-13 2020-04-10 南京慧脑云计算有限公司 一种基于磁共振成像的脑白质纤维束示踪分析方法及系统
CN111110873A (zh) * 2020-02-24 2020-05-08 苏州欣影生物医药技术有限公司 一种磁共振/核医学双模态分子影像探针的制备方法
CN111528839B (zh) * 2020-05-29 2023-06-23 北京京东方健康科技有限公司 睡眠检测方法和装置、助眠设备和方法
JP7656967B2 (ja) * 2021-05-21 2025-04-04 アニマスキュア インコーポレイテッド． イノトジオールを含む筋疾患の予防または治療用組成物
WO2025054408A1 (en) * 2023-09-07 2025-03-13 NeuroTherapia, Inc. Methods of treating cognitive impairment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010538072A (ja) * 2007-09-06 2010-12-09 ジェナエラ コーポレイション 糖尿病を治療する方法
JP2017519775A (ja) * 2014-06-23 2017-07-20 ザスロフ，マイケル 腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
WO2011066260A2 (en) * 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010538072A (ja) * 2007-09-06 2010-12-09 ジェナエラ コーポレイション 糖尿病を治療する方法
JP2017519775A (ja) * 2014-06-23 2017-07-20 ザスロフ，マイケル 腸の腸内分泌系を関連疾患又は病状の処置のために刺激する方法及び組成物

Also Published As

Publication number Publication date
EP3806862A1 (en) 2021-04-21
US20210252023A1 (en) 2021-08-19
BR112020025296A2 (pt) 2021-03-09
SG11202012343TA (en) 2021-01-28
MX2020013614A (es) 2021-05-27
AU2019285065A1 (en) 2021-01-07
WO2019241503A1 (en) 2019-12-19
CN112566641A (zh) 2021-03-26
CA3103463A1 (en) 2019-12-19
EP3806862A4 (en) 2022-07-06
KR20210009422A (ko) 2021-01-26
US20190381071A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
JP2021527090A (ja) 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物
JP7312169B2 (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
JP6957602B2 (ja) 神経変性疾患のための治療薬
ES2941769T3 (es) Tratamiento de trastornos del sistema nervioso utilizando combinaciones de agonistas de RXR y hormonas tiroideas
JP7352542B2 (ja) 運動失調を処置するためのリルゾールプロドラッグの使用
JP2021527090A5 (https=)
KR102467953B1 (ko) 리소좀 축적 질환과 관련된 약제 조성물 및 용도
AU2017277005A1 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
KR102549684B1 (ko) 신경퇴행성 질병에 대한 치료제
US20200129528A1 (en) Methods for treating blood pressure conditions using aminosterol compositions
WO2020028791A1 (en) Low dosage intranasal aminosterol dosage forms and methods of using the same
TW202539621A (zh) 用於治療巴金森氏症的治療劑
US20200038415A1 (en) Aminosterol compositions and methods of using the same for treating erectile dysfunction
Dahimene et al. Genotype-phenotype correlations in a French cohort with Becker muscular dystrophy: focus on cognitive aspects
HK40037184A (en) Use of riluzole prodrugs to treat ataxias
BR112020007657B1 (pt) Uso de leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma para tratamento da síndrome das pernas inquietas (rls)
JPWO2014088106A1 (ja) 線維筋痛症の予防または治療薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230919